Optimizing acromegaly treatment

Frontiers of Hormone Research

Volumn 38, Issue , 2010, Pages 174-183

  Bronstein, Marcello D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23244; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; CANCER INVASION; CANCER SIZE; CANCER SURGERY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; GROWTH HORMONE SECRETING ADENOMA; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; REVIEW;

ACROMEGALY; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 77955635774     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000318508     Document Type: Review

References (40)

1. Melmed S: Acromegaly; in Melmed S (ed): The Pituitary. Oxford Blackwell Science 2002: 419-454.
2. Holdaway IM, Bolland MJ, Gamble GD: A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159:89-95.
3. Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005;152:379-387.
4. Jallad RS, Musolino NR, Salgado LR, Bronstein MD: Treatment of acromegaly: Is there still a place for radiotherapy? Pituitary 2007;10:53-59.
5. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A: Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
6. Steiger M, Jost W, Grandas F, Van Camp G: Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 2009;116:179-191.
7. Bronstein MD: Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 2006;35:129-134.
8. Murray RD, Melmed S: A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008;93:2957-2968.
9. Jallad RS, Musolino NR, Salgado LR, Bronstein MD: Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005;63:168-175.
10. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acro-megaly. J Clin Endocrinol Metab 2005;90:4405-4410.
11. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G: Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91: 1397-1403.
12. Schmid HA: Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286:69-74.
13. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau J P, Enjalbert A, Jaquet P: Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140-145.
14. Higham CE, Trainer PJ: Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol 2008;93:1157-1169.
15. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759.
16. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF: Follow-up of pituitary tumor volume in patients with acromegaly treated with pegviso-mant in clinical trials. Eur J Endocrinol 2008;159: 517-523.
17. Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK, Saller B, German Pegvisomant Investigators: Experience from the German pegvi-somant observational study. Horm Res 2007; 68(suppl 5):70-73.
18. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S: Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008;93:3515-3518.
19. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G: Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003;59:492-499.
20. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A: Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J Clin Endocrinol Metab 2009; 94:1500-1508.
21. Casarini A P, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD: Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acro-megalic patient: preferential expression of soma-tostatin receptor subtype 3. J Endocrinol Invest 2006;29:826-830.
22. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen J W, Kristensen LØ, Hagen C, Ørskov H: Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endo-crinol Metab 2005;90:5627-5631.
23. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ: Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644-1646.
24. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ: Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92:4598-4601.
25. Neggers S, de Herder W, Janssen J, Feelders R, Van der Lely A: Combined treatment for acromegaly with long-acting somatostatin analogues and pegvi-somant: long-term safety up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;160:529-533.
26. Van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW: Control of tumor size and disease activity during co-treatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001;86:478-481.
27. Cozzi R, Attanasio R, Lodrini S, Lasio G: Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-215.
28. Selvarajah D, Webster J, Ross R, Newell-Price J: Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005;152: 569-574.
29. Gatta B, Hau DH, Catargi B, Roger P, Tabarin A: Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromega-lic patients. Clin Endocrinol (Oxf) 2005;63:477-478.
30. Jallad RS, Bronstein MD: Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with octreotide-LAR. Neuroendocrinology 2009;90:82-92.
31. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and soma-tostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288:154-157.
32. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S: Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007;148: 6107-6114.
33. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P: Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002;87:5545-5552.
34. Veysey MJ, Thomas LA, Mallet AI, Jenkins PJ, Besser GM, Wass JA, Murphy GM, Dowling RH: Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide-induced gallbladder stones. Gut 1999;44:675-682.
35. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G: Long-term effects of depot long-acting somatosta-tin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86:2779-2786.
36. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R: Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003;88: 5258-5265.
37. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A: Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endo-crinol 2005;152:61-66.
38. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R: Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endo-crinol Metab 2006;91:85-92.
39. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA: Surgical debulking of pituitary macroade-nomas causing acromegaly improves control by lan-reotide. Clin Endocrinol (Oxf) 2008;68:970-975.
40. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD: Does partial surgical tumour removal influence the response to octreotide-LAR in acro-megalic patients previously resistant to the soma-tostatin analogue? Clin Endocrinol (Oxf) 2007;67: 310-315.